Phase 4 N=250 The Treatment of Glabellar Frown Lines
Glabellar Frown Lines
Primary: Efficacy, Measured as the Percentage of Participants Who Responded to Treatment — 95.7; 99.2 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=391 A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides
Forehead Rhytides · Glabellar Rhytides
Primary: Percentage of Subjects With ≥2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at…
Phase 3 N=902 Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
Glabellar Lines · Lateral Canthal Lines
Primary: Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown — 769 Participants
Phase 3 N=234 MT10109L in the Treatment of Glabellar Lines
Glabellar Lines
Primary: The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND…
Phase 2 N=399 Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
Glabellar Frown Lines
Primary: Number of Composite Responders at Month 1 — 64; 71; 72; 77 Participants
Phase 2 N=42 Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
Glabellar Frown Lines (GL)
Primary: Investigator's Assessment of GL Severity at Maximum Frown Using the Facial Wrinkle Scale (FWS). — 1; 0; 0; 2 Participants
Phase 3 N=190 Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
Glabellar Lines
Primary: The Percentage of Responders at Day 29 Cycle 1 as Measured by Investigator's Live Assessment (ILA) of Glabellar Lines at Maximum Frown: DB Period — 81.6; 0.8 Adjusted…
Phase 2 N=198 AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
Glabellar Lines
Primary: Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7…
N/A N=175 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines
Facial Rhytides · Glabellar Frown Lines
Primary: Percentage of Participants Achieving a Score of None or Mild by Investigator-Assessed Facial Wrinkle Scale With Photonumeric Guide (FWS) in Forehead Lines at Maximum…
Phase 3 N=185 Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
Moderate to Severe Glabellar Lines
Primary: The Proportion of Responders at Day 29 in the ILA of Glabellar Lines at Maximum Frown. — 88.3; 1.4 Adjusted percentage of responders — p=<0.0001
Phase 3 N=300 Treatment of Moderate to Severe Glabellar Lines
Glabellar Frown Lines
Primary: Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown at One Month. — 165; 0…
Phase 3 N=638 A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Glabellar Lines
Primary: Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar…
Phase 3 N=415 MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
Glabellar Lines · Lateral Canthal Lines
Primary: The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) — 0; 78; 66 Participants
Phase 3 N=324 A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002
Glabellar Frown Lines
Primary: Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject — 70.4; 1.3 percentage of…
Phase 3 N=787 A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides
Facial Rhytides · Glabellar Rhytides
Primary: Percentage of Subjects With ≥2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at…
Phase 3 N=271 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
Moderate to Severe Glabellar Frown Lines
Primary: Composite Endpoint Treatment Success (CETS) Constituted by 2 Variables: 2-point Responders at Maximum Frown (Frown as Much as Possible) at Day 30 by Investigator's…
Phase 3 N=309 A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
Glabellar Lines
Primary: Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar…
Phase 3 N=330 A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
Glabellar Frown Lines
Primary: Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject — 67.5; 1.2 percentage of…
Phase 3 N=132 Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
Glabellar Frown Lines
Primary: Number of Responders Using the Global Aesthetic Improvement Scale (GAIS) at Month 1 — 92; 3 Participants — p=<0.001
Phase 4 N=100 A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
Upper Facial Lines
Primary: Percentage of Participants With Responder Status of 'Mostly Satisfied' or 'Very Satisfied' on the Facial Line Satisfaction Questionnaire (FLSQ) Follow Up Item 4…
N/A N=143 Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area
Cosmetic Techniques
Primary: the Change in Dynamic Strain in the Glabella Area After Injection Over Time — 6.4; 10.9; 6.6; 8.9 percent difference of neutral+dyanamic
Phase 4 N=224 Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
Glabellar Lines
Primary: Number of Subjects With a Treatment Response at Day 28 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the Facial…
Phase 3 N=213 Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
Glabellar Frown Lines
Primary: Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the…
Phase 3 N=306 Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Glabellar Frown Lines
Primary: Percentage of Subjects Who Achieved ≥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales — 74.0; 1.0 percentage of responders
Phase 3 N=303 Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Glabellar Frown Lines
Primary: Percentage of Subjects Who Achieved ≥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales — 73.6; 0 percentage of subjects
Phase 2 N=92 A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
Glabellar Lines
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 7; 15; 9; 2 Participants
Phase 2 N=570 Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
Glabellar Frown Lines
Primary: The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 Year — 235 Participants
Phase 3 N=362 Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Primary: Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30 — 0; 52.3 percentage of subjects — p=<0.0001
Phase 3 N=368 Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Primary: Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30 — 0; 49.5 percentage of subjects — p=<0.0001
Phase 3 N=708 Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
Glabellar Frown Lines
Primary: Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the…